J&J posts trial win for psoriatic arthritis pill (JNJ:NYSE)
The 552-patient study found 58% of treated patients reached a 20% joint improvement after 16 weeks, Johnson & Johnson said.
- On Saturday, Johnson & Johnson announced its once-daily oral pill Icotyde successfully eased symptoms in more patients with psoriatic arthritis than a placebo in a late-stage trial.
- Psoriatic arthritis is a chronic inflammatory condition causing pain, stiffness and swelling in joints. About 30% of patients with psoriasis also develop psoriatic arthritis, creating significant demand for effective treatment options.
- In the 552-patient trial, 58% of patients taking Icotyde saw a 20% improvement in tender and swollen joint counts after 16 weeks, compared with 41% who received a placebo.
- Johnson projects peak sales to top $5 billion for Icotyde, which faces competition from injectable biologics like AbbVie's Skyrizi and UCB's Bimzelx, as well as oral treatments Sotyktu and Otezla already on market.
- David Lee, Johnson's global immunology head, told Reuters that "Patients don't want to be overtreated, they want a treatment that fits them where they're at," emphasizing Icotyde's oral convenience versus injectable alternatives.
20 Articles
20 Articles
The Courier-Tribune
Johnson & Johnson announces ICOTYDE® (icotrokinra) delivers significant improvement in psoriatic arthritis disease activity among biologic-naive patients with once-daily targeted oral peptide
Late-breaking data from Phase 3 investigational study presented at the American College of Rheumatology Convergence show 58% of ICOTYDE-treated patients achieved an ACR20 response and 29% achieved an ACR50 response at Week 16ICOTYDE is a first-in-class IL-23R targeted oral peptide,…
J&J's once-daily pill eases psoriatic arthritis symptoms in ...
Johnson & Johnson announces ICOTYDE® (icotrokinra) delivers significant improvement in psoriatic arthritis disease activity among biologic-naive patients with once-daily targeted oral peptide - PressReach
Late-breaking data from Phase 3 investigational study presented at the American College of Rheumatology Convergence show 58% of ICOTYDE-treated patients achieved an ACR20 response and 29% achieved an ACR50 response at Week 16 ICOTYDE is a first-in-class IL-23R targeted oral peptide, demonstrating significant joint and skin improvements and a favorable safety profile in a once-daily … Continue reading "Johnson & Johnson announces ICOTYDE® (icotro…
Coverage Details
Bias Distribution
- 67% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
